WESTPORT, Conn., March 17, 2014 /PRNewswire/ -- TriStar Wellness Solutions(R), Inc. (OTCQB: TWSI), a health and wellness company that targets opportunities in the self-care and professional marketplace, announced that HemCon Medical Technologies, a wholly owned subsidiary of TWSI, has launched a global initiative to target the hemodialysis market with a new product from the chitosan line of hemostatic and antibacterial barrier devices family. With 2.1 million patients undergoing dialysis globally on a yearly basis and 8% of the population having great difficulty achieving hemostasis after the procedure, the dialysis market is valued at $27 million for problem bleeders alone, and over $370 million for the overall population1. The leading countries driving growth in the market are the US, Japan, and the European Union. Leveraging strong existing relationships in these territories, HemCon plans to release an innovative product in Q2-2014, in the meantime we are working with our partners to collect valuable clinical data to provide HemCon a strategic advantage within this market.
With the feedback from these partners we have created a dressing that fulfills all the requirements of this specific application. Dialysis patients undergo treatment three times a week and their body's natural mechanism of forming a clot to stop bleeding is compromised, causing the dialysis access sites to suffer from nuisance bleeding. Dialysis wounds are also prone to irritation and infection. Status quo treatment does not fulfill all the requirements for ideal patient care. The HemCon dialysis dressing provides superior bleeding control for these compromised patients thanks to chitosan's hemostatic properties, as well as an antibacterial barrier against at least 24 microorganisms. Catheter-related infections in hemodialysis are one of the most common causes of morbidity and mortality in patients with end-stage renal disease. Staphylococcus aureus is the most common causative organism isolated2, and the HemCon dialysis dressing provides an efficacious barrier against this organism as many other gram positive and negative strains."With our superior hemostatic properties and working as a barrier to organisms that cause infection, HemCon will strive to become a leader in hemodialysis care across the world," said Bill Shields, Sr. Vice President of Sales and Business Development for HemCon. "We look forward to targeting this key market and expanding HemCon's global reach."About HemCon Medical Technologies HemCon Medical Technologies Inc., founded in 2001, develops, manufactures, and markets innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. HemCon products are designed for use by medical professionals in hospital and clinical settings as well as military and civilian first responders where control of bleeding is of critical importance. HemCon is headquartered in Portland, Ore. With a 36,000 sq. ft. state of the art manufacturing facility, the Company has additional commercial operations in Ireland and the Czech Republic. For more information, please visit www.hemcon.com. About TriStar Wellness SolutionsTriStar Wellness Solutions®, Inc. (TWSI) is a health and wellness company that targets under-met consumer opportunities in the OTC and professional marketplace. Its core strategy plans to meet the growing demand for personalized, care solutions by leveraging proprietary innovation and healthcare technology with the rapid transformation of the healthcare marketplace to create innovative, science based solutions and brands. TriStar recently acquired HemCon Medical Technologies Inc., a developer, manufacturer, and marketer of innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. It also owns the Beaute de MamanTM brand of women's health products. Additional information is available at www.tstarwellness.com.Forward-Looking StatementThis press release for TriStar Wellness Solutions®, Inc. contains forward-looking statements. Generally, you can identify these statements because they use words like "anticipates," "believes," "expects," "future," "intends," "plans," and similar terms. These statements reflect only our current expectations. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy and actual results may differ materially from those we anticipated due to a number of uncertainties, many of which are unforeseen, including, among others, the risks we face as described our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements which apply only as of the date of this press release. To the extent that such statements are not recitations of historical fact, such statements constitute forward-looking statements that, by definition, involve risks and uncertainties. In any forward-looking statement where we express an expectation or belief as to future results or events, such expectation or belief is expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the statement of expectation of belief will be accomplished.Contact:Simona BuergiTel: (503) 245-0459simona.buergi@hemcon.comWeb site: http://www.tstarwellness.com 1 Fresenius Medical Care. 2008 report. http://reports.fmc-ag.com/reports/fmc/annual/2008/gb/english/401040/dialysis-market.html 2 Farinas MC et. al. "Infection associated with hemodialysis and peritoneal dialysis catheters" Enferm Infecc Microbiol Clin. 2008 Oct;26(8):518-26.SOURCE TriStar Wellness Solutions
AI
